<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04102995</url>
  </required_header>
  <id_info>
    <org_study_id>APH204</org_study_id>
    <nct_id>NCT04102995</nct_id>
  </id_info>
  <brief_title>A Study Investigating the Efficacy and Safety of Sepranolone in Women With Menstrual Migraine</brief_title>
  <acronym>APH204</acronym>
  <official_title>An Exploratory Phase II, Randomised, Double-blind, Placebo-controlled, Parallel-group Study Investigating the Efficacy and Safety of Sepranolone in Women With Menstrual Migraine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asarina Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Scandinavian CRO</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Asarina Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this phase 2 Proof.of Concept study is to evaluate the efficacy and safety
      of Sepranolone (UC1010) in preventing menstrual migraine attacks in adult women with migraine
      occurring between Day -2 and Day 5 of the menstrual cycle. Patients will be taking
      Sepranolone or Placebo (blinded to patient and study doctor) during the two week preceding
      the menstruation for three menstrual cycles. Effect (change from baseline) will be assessed
      by comparison of symptoms recorded daily by the patients using an electronic diary using
      validated scales for assessment of menstual migraine symptoms.

      Sepranolone is identical to an endogenous steroid.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this phase 2 Proof-of-Concept study is to evaluate the effect and safety of
      two doses of Sepranolone (UC1010) in preventing menstrual migraine attacks in adult women
      with migraine occurring between Day -2 and Day 5 of the menstrual cycle in comparison to
      placebo. Study treatment will be self-administrated as subcutaneous injections during the
      luteal phase of three consecutive menstrual cycles. Effect will be assessed by comparison of
      symptoms recorded daily by the patients using an electronic migraine diary and a validated
      rating scale for assessment the physical and functional impact of menstrual migraine symptoms
      (MPFID). Preceding the treatment period, the diagnosis of Menstrual Migraine will be
      established by verifying menstrual migraine in at least two out of three menstrual cycles of
      daily symptom ratings by the patients. This period will also constitute the baseline data.
      The effect of study medication will be assessed as the change in symptoms from baseline to
      during treatment. The reduction in average number of menstrual migraine days per menstrual
      cycle during the treatment period cycles vs. the three menstrual cycles of baseline will
      constitute the primary endpoint.

      The study will also include a follow-up (no treatment) cycle before patients final visit.

      The study is conducted in three European countries (Sweden, Finland and Denmark) and will
      randomize 84 patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 27, 2019</start_date>
  <completion_date type="Anticipated">November 2020</completion_date>
  <primary_completion_date type="Anticipated">November 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in number of menstrual migraine days</measure>
    <time_frame>Through study completion, an average of 6 months</time_frame>
    <description>Change from baseline in the average number of menstrual migraine days during three consecutive menstrual cycles</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">84</enrollment>
  <condition>Menstrual Migraine</condition>
  <arm_group>
    <arm_group_label>Sepranolone (UC1010) low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subcutaneous injection every 48 hours during the luteal phase during three menstrual cycles in women with menstrual migraine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sepranolone (UC1010) high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subcutaneous injection every 48 hours during the luteal phase during three menstrual cycles in women with menstrual migraine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subcutaneous injection every 48 hours during the luteal phase during three menstrual cycles in women with menstrual migraine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sepranolone injection low dose</intervention_name>
    <description>Subcutaneous (SC) administration</description>
    <arm_group_label>Sepranolone (UC1010) low dose</arm_group_label>
    <other_name>UC1010</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sepranolone injection high dose</intervention_name>
    <description>Subcutaneous (SC) administration</description>
    <arm_group_label>Sepranolone (UC1010) high dose</arm_group_label>
    <other_name>UC1010</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo injection</intervention_name>
    <description>Subcutaneous (SC) administration</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  have Menstrual Migraine according to the International Classification of Headache
             Disorders, 3rd edition (ICHD-3) verified in three menstrual cycles

          -  have a regular menstrual cycle of 24-35 days cycle,

          -  use double barrier contraception, intrauterine device (IUD), be truly sexually
             abstinent, or subject or her partner has been surgically sterilized,

        Exclusion Criteria:

          -  More than 10 headache days per month on average during screening phase

          -  steroid hormonal treatment during previous three months

          -  ongoing treatment with antiepileptic drugs or benzodiazepines

          -  significant medical or psychiatric condition

          -  be pregnant or plan a pregnancy within the study period
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>48 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Märta Segerdahl Storck, MD, PhD</last_name>
    <phone>+46707344533</phone>
    <email>marta.segerdahl@asarinapharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Karin Ekberg, PhD</last_name>
    <phone>+46704580045</phone>
    <phone_ext>+46704580045</phone_ext>
    <email>karin.ekberg@asarinapharma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Suomen Terveystalo Plc</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Keski-Säntti</last_name>
      <phone>+358106342042</phone>
    </contact>
    <contact_backup>
      <last_name>Koivisto</last_name>
      <phone>+358106342042</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Suomen Terveystalo Plc</name>
      <address>
        <city>Tampere</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sumelahti</last_name>
      <phone>+358306334621</phone>
    </contact>
    <contact_backup>
      <last_name>Sihvonen</last_name>
      <phone>+358306334621</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Suomen Terveystalo Plc</name>
      <address>
        <city>Turku</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nissilä</last_name>
      <phone>+358400788020</phone>
    </contact>
    <contact_backup>
      <last_name>Aalto</last_name>
      <phone>+358400788020</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>ProbarE i Lund</name>
      <address>
        <city>Lund</city>
        <state>Skane</state>
        <zip>22222</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anders Luts, MD</last_name>
      <phone>+46732300450</phone>
      <email>anders.luts@probare.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CTC Clinical Trial Center</name>
      <address>
        <city>Gothenburg</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Curiac</last_name>
      <phone>+46700823351</phone>
    </contact>
    <contact_backup>
      <last_name>Varvne</last_name>
      <phone>+46700823351</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Karolinska Trial Alliance</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hallström</last_name>
      <phone>+46735787559</phone>
    </contact>
    <contact_backup>
      <last_name>Nyberg</last_name>
      <phone>+46851772487</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>CTC Clinical Trial Consultants</name>
      <address>
        <city>Uppsala</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helena Litorp, MD, PhD</last_name>
      <phone>+4618500132</phone>
    </contact>
    <contact_backup>
      <last_name>Westin</last_name>
      <phone>+4618500132</phone>
    </contact_backup>
  </location>
  <location_countries>
    <country>Finland</country>
    <country>Sweden</country>
  </location_countries>
  <removed_countries>
    <country>Denmark</country>
  </removed_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>September 23, 2019</study_first_submitted>
  <study_first_submitted_qc>September 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 25, 2019</study_first_posted>
  <last_update_submitted>May 13, 2020</last_update_submitted>
  <last_update_submitted_qc>May 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
    <mesh_term>Premenstrual Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pregnanolone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

